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Background. We sought to characterize the pharmacodynamic profile of the more intensive vancomycin dosing regimens currently used in response to the recent vancomycin guidelines.
Methods. A series of Monte Carlo simulations was performed for vancomycin regimens ranging from .5 g intravenous (IV) Q12H to 2 g IV Q12H. The probability of achieving an AUC/MIC ratio > 400 for each dosing regimen was calculated for minimum inhibitory concentrations (MICs) from .5 to 2 mg/L. The risk of nephrotoxicity for each regimen was derived from a previously published vancomycin trough-nephrotoxicity logistic regression function. Restricted analyses were performed that only included subjects with troughs between 15 and 20 mg/L.
Results. At a MIC of 2 mg/L, even the most aggressive dosing regimen considered (2 g every 12 h) only yielded a probability of target attainment (PTA) of 57% while generating a nephrotoxicity probability upward of 35% . At a MIC of 1 mg/L, >3 g per day provided PTA in excess of 80% but were associated with unacceptable risks of nephrotoxicity. In the restricted analyses of subjects with troughs between 15 and 20 mg/L, all regimens produced a PTA of 100% at MICs <1 mg/L. The PTA was variable among the regimens at a MIC of 2 mg/L and was highly dependent on the total daily dose administered.
Conclusions. This study indicates that vancomycin may not be useful for treating serious methicillin-resistant Staphylococcus aureus (MRSA) infections with MIC values . 1 mg/L where PTA is questionable. Since an AUC/MIC ratio > 400 is target associated with efficacy, one should consider incorporating computation of AUC when monitoring vancomycin.
Despite the widespread use of vancomycin in response to increases in the incidence of methicillin-resistant Staphylococcus aureus (MRSA) both in hospital and the community, there has been an inadequate examination of its exposure-response profile against MRSA [1, 2] . The recent vancomycin therapeutic monitoring guidelines recommend more aggressive vancomycin dosing schemes, maintaining vancomycin troughs between 15 and 20 mg/L ''based on the potential to increase the probability of optimal target serum vancomycin concentrations, and improve clinical outcomes for complicated infections caused by S. aureus'' [3] . However, studies characterizing the pharmacodynamic profile of the more intensive vancomycin dosing regimens used in response to the guidelines have not been performed.
When evaluating the exposure-response profile of an antibiotic, there are several things to consider. First, therapy should have a high likelihood of achieving the exposure target associated with maximal response among the pathogens likely to be encountered in clinical practice. While a variety of pharmacodynamic indices have been suggested for vancomycin, data suggest that a near maximal bactericidal effect is achieved against MRSA when the ratio of the vancomycin area under the concentration-time curve and the minimum inhibitory concentrations (AUC/MIC) exceeds 400 [4] [5] [6] [7] .
Examination of effect alone is not sufficient when describing the exposure-response profile of an antibiotic. It is also critical to assess the probability of toxicity associated with the regimens used in practice. While the association between vancomycin and neprotoxicity has been the subject of considerable debate, recent data suggests that vancomycin exposure-nephrotoxicity response relationship exists and the initial vancomycin trough is the pharmacodynamic index that best describes this association [8] [9] [10] [11] [12] [13] .
Finally, it is important to recognize that to truly understand the relationship between drug exposure and the response, these relationships must be viewed in an integrated fashion. This investigation sought to characterize exposure-response profiles of the more intensive empiric vancomycin dosing regimens currently used in practice in response to the recent vancomycin guidelines. Monte Carlo simulation was used to quantify the probability of target attainment (PTA) profile and the risk of nephrotoxicity for vancomycin dosing schemes of varying intensity over the range of MRSA MIC values deemed susceptible by CLSI [14] . Since vancomycin is renally excreted from the body and exposure changes as a function of creatinine clearance (CL CR ), we evaluated these exposure-response relationships across different renal function strata. We also examined the pharmacodynamic profile of maintaining troughs between 15-20 mg/L and 10-15 mg/L.
METHODS

Vancomycin Population Pharmacokinetic Model
Vancomycin exposure profiles were estimated from a previously published open 2-compartment population pharmacokinetic (PK) model of 37 patients with varying degrees of renal function who received vancomycin therapy for a presumed or documented Gram-positive infection [15] [16] [17] 
Monte Carlo Simulation
A series of 9999 subject Monte Carlo simulations (MCS) were performed for vancomycin dosing regimens using total daily doses ranging from 1 to 4 g in 1 g increments, divided every 12 h (500 mg intravenous [IV] Q12H, 1000 mg IV Q12H, 1500 mg IV Q12H, and 2000 mg IV Q12H) [18] . For each simulated regimen, the estimated CL CR was fixed at values of 1.2, 2.4, 3.6, 4.8, 6.0, and 7.2 L/h. Parameter values from the lognormal distributions were used to simulate plasma concentration-time curves for dosing regimens. Plasma concentration-time profiles were not adjusted for protein binding.
The AUC 72-96h was determined for each regimen at the 6 prespecified CL CR values. The AUC 72-96h was calculated by integrating the plasma concentration-time profile from time zero (start of administration) to 72 and 96 h after start of administration and taking the difference between AUC 0-72h and AUC 0-96h. For each regimen simulated, the fraction of subjects achieving an AUC 72-96h /MIC ratio >400 within each CL CR stratum was calculated for MIC values from .5 mg/L to 2 mg/L. The AUC 72-96h was used as the AUC exposure endpoint for efficacy because it closely approximates 24-h steady state AUC values (AUC exposure evaluated in previous analyses) and aligns with the Cmin 96h endpoint for toxicity (see below).
To assess probability of toxicity, vancomycin trough concentrations at hour 96 (Cmin 96h ) were simulated for each regimen at the 6 prespecified CL CR values. The initial vancomycin trough nephrotoxicity logistic regression function from our previous publication was used to assess the median (interquartile range) probability of nephrotoxicity for each of the simulated vancomycin dosing regimens within each CL CR stratum [8] . The likelihood of nephrotoxicity was estimated separately for intensive care unit (ICU) and non-ICU patients. Since our initial model was derived from a population with initial trough ,30 mg/L, we did not estimate the probability of nephrotoxicity for CL CR strata with estimated median trough in excess of 30 mg/L [8] .
INTEGRATED PROBABILITY OF TARGET ATTAINMENT AND NEPHROTOXICITY ANALYSIS
To estimate overall probability of achieving an AUC/MIC ratio >400 and risk of nephrotoxicity for each vancomycin regimen, a 9999 subject Monte Carlo simulation was performed for each of the 4 vancomycin dosing regimens using the mean (standard deviation) CL CR value from a 415-subject nosocomial pneumonia (NP) clinical trial as the estimate of CL CR variability [19] . The mean (standard deviation) for this population was 5.3 (2.58) L/h. The AUC 72-96h and Cmin 96h was estimated for each regimen, and the fraction of subjects achieving an AUC/MIC ratio >400 for MIC values of .5 mg/L to 2 mg/L was calculated. The risk of a nephrotoxic event among ICU and non-ICU patients for each regimen was determined as described above. Restricted analyses were also performed that only included subjects among the 4 simulated vancomycin regimens that achieved Cmin 96h values between 15-20 and 10-15 mg/L. In these restricted analyses, the fraction of subjects achieving an AUC/MIC ratio >400 for MIC values of .5 to 2 mg/L was calculated for each regimen.
RESULTS
The median (IQR) AUC 72-96h and Cmin 96h values, stratified by CL CR , for the vancomycin dosing regimens from the MCS analysis are displayed in The probability of achieving an AUC/MIC ratio >400, stratified by MIC value and CL CR , is displayed in Table 2 . At a MIC value of .5 mg/L, the PTA exceeded 80% across CL CR values when the total daily vancomycin dose was >2 g. At a MIC value of 1 mg/L, the probability of achieving an AUC/MIC > 400 was variable. The PTA was ,80% for most CL CR strata with 500 mg IV Q12H or 1000 mg IV Q12H. In contrast, the PTA exceeded 80% with 1500 mg IV Q12H or 2000 mg IV Q12H for most CL CR strata. At a MIC of 2 mg/L, the probability of achieving an AUC/MIC > 400 was ,80% for all regimens except 2 g IV Q12H at CL CR values of 1.2 and 2.4 L/h. The probability of a nephrotoxic event for each vancomycin dosing regimen, stratified by ICU status and CL CR , is displayed in Table 3 . Across all CL CR strata, there was a dose-response relationship between ascending daily doses of vancomycin administered and the risk of nephrotoxicity and likelihoods were highest among ICU subjects. At all doses evaluated, the probability of a nephrotoxic event and CL CR were inversely related.
Using the distribution of CL CR from a NP clinical trial [19] , the overall probability of achieving an AUC/MIC ratio >400 and risk of nephrotoxicity for each vancomycin dosing regimen is displayed in Table 4 . Both the overall PTA and probability of a nephrotoxic event increased as the intensity of the vancomycin daily dose increased. The probability of a nephrotoxic event also increased as a function of dosing frequency and ICU status. Similar to the stratified CL CR PTA analyses, PTA was suboptimal at an MIC value of 2 mg/L. At a MIC of 1 mg/L, >3 total g per day provided PTA in excess of 80%, but these dosing schemes were associated with considerable risks of nephrotoxicity, especially for subjects in the ICU.
The results of the restricted analysis that assessed probability of achieving an AUC/MIC ratio >400 for MIC values of .5 to 2 mg/L among subjects with Cmin 96h values between 15-20 and 10-15 mg/L for each simulated regimen are displayed in Figures  1 and 2 , respectively. When Cmin 96h values were restricted to 15-20 mg/L, the observed PTA was 100% at MIC values of .5 and 1 mg/L for all regimens. In contrast, the PTA was variable among the regimens at a 2 mg/L and was highly dependent on the daily dose administered. A more favorable PTA at a 2 mg/L was observed with higher daily doses relative to lower daily doses yielding the same trough range (15-20 mg/L). When the analysis For MRSA infections with a MIC value of 1 mg/L, the PTA values were improved relative to those seen at an MIC of 2 mg/L. Despite this improvement in PTA, the PTA was highly variable across CL CR strata when daily doses of <2 g were used. Vancomycin regimens consisting of at least 3 g daily were necessary to achieve PTA values 80% at a MIC value of 1 mg/L. However, dosing regimens containing at least 3 g daily were associated with an elevated risk of nephrotoxicity, especially among subjects with lower CL CR values and for those residing in the ICU. It was only at a MIC value of .5 mg/L when both PTA and nephrotoxicity risks were highly acceptable at doses .1 g per day. This may be the only scenario where vancomycin can be effectively used without an excessive probability of a nephrotoxic event.
Another noteworthy finding in our analysis was the high degree of variability between AUC 72-96h and Cmin 96h values. The recent vancomycin guidelines recommend monitoring trough concentrations as a surrogate for AUC values. This recommendation is troubling because we observed a wide range of AUC values from several different dosing regimens yielding isometric Cmin values and vice versa. The AUC 72-96h associated with a given trough value was highly dependent on the daily dose administered and the CL CR .
The therapeutic discordance between AUC 72-96h and Cmin 96h values is further highlighted by the restricted PTA analyses, which only considered subjects with Cmin of 15-20 mg/L for each simulated regimen (Figure 1) . Although PTA was highly acceptable for MIC values <1 mg/L for all regimens, PTA at 2 mg/L was variable and highly dependent on the daily dose administered. This finding is not surprising because the AUC is the integrated quantity of drug exposure (the serum drug concentration time curve) over a defined interval and reflects the cumulative exposure over time. In contrast, the Cmin represents a single exposure point at the end of the dosing interval. It is unreasonable to expect a single exposure point at the end of the dosing interval to be representative of the entire concentration-time interval. It is also important to note that, while PTA was variable, the risk of nephrotoxicity was the same for all regimens producing Cmin values of 15-20 mg/L, regardless of total daily dose, since nephrotoxicity is more closely linked to the Cmin than the AUC. While Cmin appears to be a good marker of likelihood of toxicity, these data call into question the practice of monitoring trough values for effect. Our data demonstrated that Cmin values between 15 and 20 mg/L do not consistently result in AUC/MIC ratios >400 when the MIC is 2 mg/L. Conversely, regimens producing troughs of 15-20 mg/L are not always needed to achieve an AUC/MIC ratios >400 when the MIC is 1 mg/L. Since an AUC/MIC ratio >400 is considered to be the most important pharmacodynamic parameter associated with positive clinical outcome, one should consider incorporating computation of AUC when monitoring vancomycin therapy rather than solely using Cmin as a surrogate for both effect and toxicity. We support the use of Cmin monitoring for assessment of a subject's probability of experiencing a nephrotoxic event while on vancomycin therapy but believe AUC calculations are warranted if AUC/MIC ratio >400 is truly the pharmacodynamic target of interest, especially when the MIC value is 2 mg/ L. Calculation of AUC can be accomplished by dividing the daily dose by clearance, where clearance is estimated by CL CR . Alternatively, CL V can be more accurately calculated in a patient by taking 2 or 3) timed sample measurements (ie, Cmax and Cmin). Although, determination of the vancomycin Cmax has been promoted as unnecessary, measurement of this value can improve estimation of AUC to optimize effect.
Our findings also question the need for trough values of 15-20 mg/L for all patients. Our results indicate that regimens producing trough values in excess of 15 mg/L are not always necessary to provide an AUC/MIC ratio >400, especially if the MIC is <1 mg/L (Figure 2) . By minimizing the trough needed to achieve the desired AUC value, we may be able to reduce the risk of nephrotoxicity associated with vancomycin.
Several things should be noted when interpreting these results. First, the pharmacodynamic target for vancomycin (AUC/ MIC ratio >400) against MRSA is based on limited clinical data. The best data available are from a retrospective evaluation of patients with S. aureus in a community hospital over a 1 year period [4] . There were only a small number of MRSA isolates in the database, and a number of the patients had combination agent chemotherapy. Nonetheless, a number of different analyses identified AUC/MIC ratios of 350-400 (total drug) as being related to clinical outcome for patients with Staphylococcal nosocomial pneumonia, and this is consistent with in vitro and animal model studies [4] [5] [6] [20] [21] [22] [23] [24] . Although these are the best available data to date, it highlights the major importance in identifying a better estimate of the pharmacodynamic target for good clinical response than that currently available.
Second, the pharmacodynamic target for vancomycin (AUC/ MIC ratio >400) was based on broth microdilution (BMD) MIC testing [4] . Similar to most mathematical expressions, the denominator drives this relationship. The higher the MIC value, the lower the measure of drug exposure relative to the MIC and the lower the level of the expected microbiological effect. This is important to note because of the increased use of Etest to quantify MIC values and data showing Etest yield higher MIC values relative to BMD for a given MRSA strain [25] . For now, our results should be viewed in relation to BMD results and clinical studies are needed to define the AUC/MIC ratio needed for maximal effect using the Etest as the measure of potency.
Third, there is little information available with regard to the protein binding of vancomycin. Previous reports have differed considerably with respect to the amount of free drug [26] . It is therefore a high priority to identify the range of protein binding observed clinically for this agent so that the free drug AUC/MIC ratio target can be properly estimated and the true therapeutic window for vancomycin be elucidated for seriously ill patients. Fourth, our results only apply to serious infections due to MRSA. Our results should not be generalized for less severe infection types and other pathogens.
Overall, this study demonstrated that the utility of vancomycin be questioned for MRSA isolates with an MIC .1.0 mg/L where PTA is questionable. Total daily doses of vancomycin <4 g were not able to achieve an acceptable PTA for infections with an MIC value of 2 mg/L. For infections with an MIC value of 1 mg/L, only aggressive doses of vancomycin were able to achieve a satisfactory PTA but with a high risk of nephrotoxicity, especially for patients residing in the ICU. Given the prevalence of patients with MRSA infections with MIC values .1 mg/L, our results indicate that vancomycin cannot safely achieve the desired PD target. In these patients, alternative anti-MRSA agents should be considered. Before other agents can be definitively recommended over vancomycin, data are sorely needed to determine whether alternative antibiotic can remedy the outcomes observed with vancomycin for MRSA infections with high vancomycin MIC values .1 mg/L. In addition, further studies are needed to determine if optimization of vancomycin therapy can improve outcomes without subjecting patients to an increased risk of vancomycin-related toxicities.
